Efficacy of Antiviral Agents against the SARS-CoV-2 Omicron Subvariant BA.2

  • Takashita, Emi Ph.D.
  • Kinoshita, Noriko M.D.
  • Yamayoshi, Seiya D.V.M., Ph.D.
  • Sakai-Tagawa, Yuko Ph.D.
  • Fujisaki, Seiichiro Ph.D.
  • Ito, Mutsumi D.V.M.
  • Iwatsuki-Horimoto, Kiyoko D.V.M., Ph.D.
  • Halfmann, Peter Ph.D.
  • Watanabe, Shinji D.V.M., Ph.D.
  • Maeda, Kenji M.D., Ph.D.
  • Imai, Masaki D.V.M., Ph.D.
  • Mitsuya, Hiroaki M.D., Ph.D.
  • Ohmagari, Norio M.D., Ph.D.
  • Takeda, Makoto M.D., Ph.D.
  • Hasegawa, Hideki M.D., Ph.D.
  • Kawaoka, Yoshihiro D.V.M., Ph.D.

  • 1National Institute of Infectious Diseases, Tokyo, Japan

    2National Center for Global Health and Medicine, Tokyo, Japan

    3University of Tokyo, Tokyo, Japan

    4University of Wisconsin-Madison, Madison, WI

    5University of Tokyo, Tokyo, Japan [email protected]

Drs. Takashita, Kinoshita, and Yamayoshi contributed equally to this letter.

This letter was published on March 9, 2022, at NEJM.org.

Supported by grants from the Center for Research on Influenza Pathogenesis (HHSN272201400008C, to Dr. Kawaoka), and from the Center for Research on Influenza Pathogenesis and Transmission (75N93021C00014, to Dr. Kawaoka), funded by the National Institute of Allergy and Infectious Diseases, and by a Research Program on Emerging and Reemerging Infectious Diseases (JP20fk0108412 and JP21fk0108615, to Dr. Kawaoka; JP21fk0108104, to Dr. Watanabe), a Project Promoting Support for Drug Discovery (JP20nk0101632, to Dr. Kawaoka), the Japan Program for Infectious Diseases Research and Infrastructure (JP21wm0125002, to Dr. Kawaoka) from the Japan Agency for Medical Research and Development, and a Grant-in-Aid for Emerging and Reemerging Infectious Diseases from the Ministry of Health, Labor, and Welfare, Japan (20HA2007, to Dr. Hasegawa).

Disclosure forms provided by the authors are available with the full text of this letter at NEJM.org.

New England Journal of Medicine 386(15):p 1475-1477, April 14, 2022. | DOI: 10.1056/NEJMc2201933

Omicron BA.2 Subvariant and Antiviral Agents

The in vitro activity of monoclonal antibodies and antiviral agents was assessed against the sublineages of the SARS-CoV-2 variant of concern omicron (BA.1, BA.1.1, and BA.2). Variable activity of the monoclonal antibodies was observed.

Resistance Mutations in SARS-CoV-2 Delta Variant after Sotrovimab Use

  • Rockett, Rebecca Ph.D.
  • Basile, Kerri M.D.
  • Maddocks, Susan M.D., Ph.D.
  • Fong, Winkie Ph.D.
  • Agius, Jessica E. Ph.D.
  • Johnson-Mackinnon, Jessica Ph.D.
  • Arnott, Alicia Ph.D.
  • Chandra, Shona Ph.D.
  • Gall, Mailie Ph.D.
  • Draper, Jenny Ph.D.
  • Martinez, Elena Ph.D.
  • Sim, Eby M. Ph.D.
  • Lee, Clement B.S.
  • Ngo, Christine B.S.
  • Ramsperger, Marc Ph.D.
  • Ginn, Andrew N. Ph.D.
  • Wang, Qinning Ph.D.
  • Fennell, Michael M.S.
  • Ko, Danny B.S.
  • Lim, Ling H. M.D.
  • Gilroy, Nicky M.D.
  • O’Sullivan, Matthew V.N. M.D., Ph.D.
  • Chen, Sharon C.-A. M.D., Ph.D.
  • Kok, Jen M.D., Ph.D.
  • Dwyer, Dominic E. M.D.
  • Sintchenko, Vitali M.D., Ph.D.
New England Journal of Medicine 386(15):p 1477-1479, April 14, 2022. | DOI: 10.1056/NEJMc2120219
Copyright © 2022 Massachusetts Medical Society. All rights reserved.
View full text|Download PDF